\nViridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2026.<\/p>\n
\n\u201cWe are very encouraged by the early indications from our recent launch of Lumvoa as we start a new chapter for Viridian as a commercial-stage company,\u201d said Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics. \u201cOur team\u2019s focus on execution continues in the commercial setting and we are happy with the early launch feedback from physicians and patients, positive payer engagement, and our progress in building enthusiasm for Lumvoa as a new treatment option. In parallel, we continue to advance our R&D pipeline toward a planned BLA submission for elegrobart in the first quarter of 2027, and are on track to deliver on clinical development milestones for our FcRn and TSHR programs in the second half of this year. With a strong balance sheet, we are well positioned to continue executing across our commercial and development priorities.\u201d<\/p>\n
Recent Business Highlights<\/span><\/b><\/p>\n TED PORTFOLIO<\/b><\/p>\n FCRN PORTFOLIO<\/b><\/p>\n Financial Results<\/span><\/strong><\/p>\n About Viridian Therapeutics<\/span><\/b><\/p>\n \nViridian Therapeutics is a biotechnology company dedicated to developing better medicines for patients with autoimmune and rare diseases. Utilizing our expertise in antibody discovery and protein engineering, we aim to build on proven science to develop innovative medicines that address unmet needs and improve patient outcomes.<\/p>\n \nWith an immediate focus in thyroid eye disease (TED), we developed Lumvoa, a full IGF-1R antagonist approved by the U.S. FDA for the treatment of thyroid eye disease. We are also advancing elegrobart, a late-stage investigational subcutaneous therapy designed to further address unmet needs in TED and improve patient convenience. Beyond TED, we are advancing a pipeline of potential best-in-class medicines to address multiple serious autoimmune diseases.<\/p>\n \nViridian is headquartered in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com<\/a>. Follow Viridian on LinkedIn<\/a> and X<\/a>.<\/p>\n Forward Looking Statements<\/span><\/b><\/p>\n \nThis press release contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, \u201canticipate,\u201d \u201cbelieve,\u201d \u201cbecome,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cdesign,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con track,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d or \u201cwould\u201d or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: the commercialization of Lumvoa, including early indications of launch; that the company\u2019s current commercial and medical affairs infrastructure will support and accelerate an elegrobart launch; preclinical development, clinical development, and anticipated commercialization of Viridian\u2019s product candidates, elegrobart, VRDN-006, and VRDN-008, including the company\u2019s intention to communicate development plans for VRDN-006 in 2026; anticipated data results and timing of their disclosure, including VRDN-008 phase 1 healthy volunteer data expected in the second half of 2026; Viridian\u2019s expectations regarding the anticipated timing or likelihood of regulatory submissions and approvals, including a BLA submission for elegrobart in the first quarter of 2027 and an IND submission for the company\u2019s TSHR program in the fourth quarter of 2026; elegrobart\u2019s potential to be the first subcutaneous therapy for the treatment of TED with a planned low-volume autoinjector that patients can self-administer at home; Viridian\u2019s product candidates potentially being best-in-class; Viridian\u2019s expectations regarding the potential commercialization, market size, and market opportunities of veligrotug and elegrobart, if approved; and that Viridian\u2019s cash and anticipated commercial revenues from Lumvoa and, if approved, elegrobart, will be sufficient to fund its business plans through profitability.<\/p>\n \nNew risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: that the company has historically incurred losses and may not be able to secure additional capital when needed; that prior to marketing approval of veligrotug, the company had not generated revenue from product sales; that the company may be unable to maintain commercial manufacturing, sales and marketing capabilities or enter into agreements with third parties to commercially manufacture, market and sell veligrotug; market acceptance of veligrotug; potential utility, efficacy, potency, safety, clinical benefits, clinical response, and convenience of veligrotug and Viridian\u2019s product candidates; that results or data from completed or ongoing clinical trials may not be representative of the results of ongoing or future clinical trials; that preliminary data may not be representative of final data; the timing, progress and plans for our ongoing or future research, preclinical, and clinical development programs; changes to trial protocols for ongoing or new clinical trials; expectations and changes regarding the timing for regulatory filings; regulatory interactions; expectations and changes regarding the timing for enrollment and data; uncertainty and potential delays related to clinical drug development; the duration and impact of regulatory delays in our clinical programs; the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates; manufacturing risks; competition from other therapies or products; estimates of market size and market opportunity; other matters that could affect the sufficiency of existing cash, cash equivalents, and short-term investments to fund operations; our financial position; our future operating results and financial performance; Viridian\u2019s intellectual property position; the timing of preclinical and clinical trial activities and reporting results from same; that our product candidates may not be commercially successful, if approved; and other risks described from time to time in the \u201cRisk Factors\u201d section of our filings with the Securities and Exchange Commission, including those described in our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as applicable, and supplemented from time to time by our Current Reports on Form 8-K. Any forward-looking statement speaks only as of the date on which it was made. Neither the company, nor its affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date hereof.<\/p>\n 2026<\/b><\/p>\n<\/td>\n 2025<\/b><\/p>\n<\/td>\n<\/tr>\n \n$<\/p>\n<\/td>\n \n233<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n51<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n75<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n284<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n75<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n71,577<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n86,626<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n54,975<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n20,216<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n126,552<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n106,842<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n(126,268<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(106,767<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n(851<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n6,032<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n$<\/p>\n<\/td>\n \n(127,119<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(100,735<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n$<\/p>\n<\/td>\n \n(112,824<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(81,978<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n$<\/p>\n<\/td>\n \n(1.05<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(1.00<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n107,884,104<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n81,593,463<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n$<\/p>\n<\/td>\n \n(9,395<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(9,034<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n$<\/p>\n<\/td>\n \n(69.72<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(66.99<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n134,754<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n134,864<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n$<\/p>\n<\/td>\n \n(4,899<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(9,723<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n$<\/p>\n<\/td>\n \n(69.72<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(66.98<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n70,270<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n145,160<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n 2026<\/b><\/p>\n<\/td>\n 2025<\/b><\/p>\n<\/td>\n<\/tr>\n \n$<\/p>\n<\/td>\n \n981,530<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n874,652<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n75,000<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n40,703<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n24,766<\/p>\n<\/td>\n<\/tr>\n \n$<\/p>\n<\/td>\n \n1,097,233<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n899,418<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n435,136<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n177,251<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n662,097<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n722,167<\/p>\n<\/td>\n<\/tr>\n \n$<\/p>\n<\/td>\n \n1,097,233<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n899,418<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\u00a0<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260806919095\/en\/<\/a><\/span><\/p>\n Investors Media KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Optical Clinical Trials<\/p>\n\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n \u00a0<\/td>\n<\/tr>\n \n Viridian Therapeutics, Inc.<\/b><\/td>\n<\/tr>\n \n Condensed Consolidated Statements Of Operations<\/b><\/td>\n<\/tr>\n \n (In thousands, except share and per share data)<\/b><\/td>\n<\/tr>\n \n (Unaudited)<\/b><\/td>\n<\/tr>\n \n \n \u00a0<\/td>\n<\/tr>\n \n \n Three Months Ended<\/b><\/td>\n<\/tr>\n \n \n June 30,<\/b><\/td>\n<\/tr>\n \n \n \n \u00a0<\/td>\n \n \n Revenues:<\/td>\n \n \u00a0<\/td>\n <\/tr>\n \n License revenue<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Collaboration revenue – related parties<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Total revenues<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Operating expenses:<\/td>\n \n \u00a0<\/td>\n <\/tr>\n \n Research and development<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Selling, general and administrative<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Total operating expenses<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Loss from operations<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Total other income (expense), net<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Net loss<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Net loss allocated to common stock<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Net loss per share, basic and diluted, common stock<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Weighted-average common shares outstanding, basic and diluted<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Net loss allocated to Series A convertible preferred stock<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Net loss per share, basic and diluted, Series A convertible preferred stock<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Weighted-average Series A convertible preferred stock outstanding, basic and diluted<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Net loss allocated to Series B convertible preferred stock<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Net loss per share, basic and diluted, Series B convertible preferred stock<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n Weighted-average Series B convertible preferred stock outstanding, basic and diluted<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \n
\n \u00a0<\/td>\n<\/tr>\n \n Viridian Therapeutics, Inc.<\/b><\/td>\n<\/tr>\n \n Condensed Consolidated Balance Sheets<\/b><\/td>\n<\/tr>\n \n (In thousands)<\/b><\/td>\n<\/tr>\n \n (Unaudited)<\/b><\/td>\n<\/tr>\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n June 30,<\/b><\/td>\n \n December 31,<\/b><\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Cash, cash equivalents and marketable securities<\/td>\n \n \n \n \n \n \n Other receivable<\/td>\n \n \n \n \n \n \n Other assets<\/td>\n \n \n \n \n \n \n Total assets<\/td>\n \n \n \n \n \n \n Total liabilities<\/td>\n \n \n \n \n \n \n Total stockholders\u2019 equity<\/td>\n \n \n \n \n \n \n Total liabilities and stockholders\u2019 equity<\/td>\n \n \n \n \n \n <\/p>\n
\n<\/b>
Greg Rossino
\n
grossino@viridiantherapeutics.com<\/a><\/p>\n
\n<\/b>
Lisa Lopez
\n
llopez@viridiantherapeutics.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260806919095\/en\/2003056\/3\/Viridian_Logo_-_Jan.jpg\"){kind=logo}
<\/td>\n<\/tr>\n